Free Trial
→ Elon pays this company. Every time. (From Behind the Markets) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Enveric Biosciences, Inc. stock logo
ENVB
Enveric Biosciences
$1.37
-2.3%		$1.47
$1.17
▼
$13.25
$6.13M1.181.38 million shs150,742 shs
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
$2.70
-3.6%		$6.67
$2.43
▼
$21.60
$5.70M0.6129,765 shs101,447 shs
Orgenesis Inc. stock logo
ORGS
Orgenesis
$0.35
+400.0%		$0.36
$0.00
▼
$1.00
$1.81M2.861,005 shs778 shs
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
$0.48
-4.1%		$0.49
$0.26
▼
$15.40
$6.23M0.48317,733 shs22,474 shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Enveric Biosciences, Inc. stock logo
ENVB
Enveric Biosciences
-4.76%-4.76%-1.41%+6.06%-81.93%
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
-14.37%-13.58%-29.47%-68.26%-79.33%
Orgenesis Inc. stock logo
ORGS
Orgenesis
-80.00%-80.00%-80.00%+268.42%-93.00%
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
+1.08%-3.07%-0.94%-15.23%-96.04%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Enveric Biosciences, Inc. stock logo
ENVB
Enveric Biosciences
$1.37
-2.3%		$1.47
$1.17
▼
$13.25
$6.13M1.181.38 million shs150,742 shs
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
$2.70
-3.6%		$6.67
$2.43
▼
$21.60
$5.70M0.6129,765 shs101,447 shs
Orgenesis Inc. stock logo
ORGS
Orgenesis
$0.35
+400.0%		$0.36
$0.00
▼
$1.00
$1.81M2.861,005 shs778 shs
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
$0.48
-4.1%		$0.49
$0.26
▼
$15.40
$6.23M0.48317,733 shs22,474 shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Enveric Biosciences, Inc. stock logo
ENVB
Enveric Biosciences
-4.76%-4.76%-1.41%+6.06%-81.93%
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
-14.37%-13.58%-29.47%-68.26%-79.33%
Orgenesis Inc. stock logo
ORGS
Orgenesis
-80.00%-80.00%-80.00%+268.42%-93.00%
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
+1.08%-3.07%-0.94%-15.23%-96.04%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Enveric Biosciences, Inc. stock logo
ENVB
Enveric Biosciences
1.00
SellN/AN/A
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
2.00
Hold$22.50733.33% Upside
Orgenesis Inc. stock logo
ORGS
Orgenesis
0.00
N/AN/AN/A
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
2.20
Hold$53.3311,128.07% Upside

Current Analyst Ratings Breakdown

Latest ORGS, LEXX, ENVB, and RVPH Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/2/2026
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeSell (D-) ➝ Sell (E+)
9/16/2026
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeSell (E+) ➝ Sell (D-)
7/24/2026
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeSell (D-) ➝ Sell (E+)
7/17/2026
Enveric Biosciences, Inc. stock logo
ENVB
Enveric Biosciences
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (E+)
(Data available from 10/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Enveric Biosciences, Inc. stock logo
ENVB
Enveric Biosciences
N/AN/AN/AN/A$7.00 per shareN/A
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
$710K8.02N/AN/A$2.00 per share1.35
Orgenesis Inc. stock logo
ORGS
Orgenesis
$662K2.73N/AN/A($6.58) per share-0.05
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
N/AN/AN/AN/A$1.48 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Enveric Biosciences, Inc. stock logo
ENVB
Enveric Biosciences
-$8.77M-$12.65N/AN/AN/AN/A-168.04%-145.95%11/12/2026 (Estimated)
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
-$11.90M-$5.10N/AN/AN/AN/A-174.93%-143.89%10/28/2026 (Estimated)
Orgenesis Inc. stock logo
ORGS
Orgenesis
-$55.36M-$11.51N/AN/AN/A-3,827.81%N/A-130.18%11/11/2026 (Estimated)
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
-$19.86M-$1.85N/AN/AN/AN/A-391.58%-119.08%11/12/2026 (Estimated)

Latest ORGS, LEXX, ENVB, and RVPH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/11/2026N/A
Orgenesis Inc. stock logo
ORGS
Orgenesis
-$2.60N/AN/AN/A$2.80 millionN/A
10/28/2026Q4 2026
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
-$0.90N/AN/AN/A$0.05 millionN/A
8/14/2026Q2 2026
Enveric Biosciences, Inc. stock logo
ENVB
Enveric Biosciences
N/A-$0.76N/A-$0.76N/AN/A
8/13/2026Q2 2026
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
-$0.3850-$0.19+$0.1950N/AN/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Enveric Biosciences, Inc. stock logo
ENVB
Enveric Biosciences
N/AN/AN/AN/AN/A
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
N/AN/AN/AN/AN/A
Orgenesis Inc. stock logo
ORGS
Orgenesis
N/AN/AN/AN/AN/A
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Enveric Biosciences, Inc. stock logo
ENVB
Enveric Biosciences
N/A
10.21
10.21
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
N/A
10.61
10.61
Orgenesis Inc. stock logo
ORGS
Orgenesis
N/A
0.07
0.07
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
N/A
2.08
2.08

Institutional Ownership

CompanyInstitutional Ownership
Enveric Biosciences, Inc. stock logo
ENVB
Enveric Biosciences
13.82%
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
13.06%
Orgenesis Inc. stock logo
ORGS
Orgenesis
22.56%
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
63.18%

Insider Ownership

CompanyInsider Ownership
Enveric Biosciences, Inc. stock logo
ENVB
Enveric Biosciences
2.41%
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
8.39%
Orgenesis Inc. stock logo
ORGS
Orgenesis
1.91%
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
8.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Enveric Biosciences, Inc. stock logo
ENVB
Enveric Biosciences
64.48 million4.37 millionNot Optionable
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
72.11 million1.93 millionNot Optionable
Orgenesis Inc. stock logo
ORGS
Orgenesis
1505.17 million4.53 millionNo Data
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
1413.11 million11.67 millionOptionable

Recent News About These Companies

Reviva Pharmaceuticals op Lytham Partners: brilaroxazine vordert
September 29, 2026  |  nl.investing.comhttps://nl.investing.com/news/transcripts/reviva-pharmaceuticals-op-lytham-partners-brilaroxazine-vordert-93CH-926870
Reviva Pharmaceuticals alla conferenza Lytham Partners: avanza brilaroxazine
September 29, 2026  |  it.investing.comhttps://it.investing.com/news/transcripts/reviva-pharmaceuticals-alla-conferenza-lytham-partners-avanza-brilaroxazine-93CH-3567624
Reviva to Participate in the Lytham Partners Fall 2026 Investor Conference
September 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/22/3366238/0/en/reviva-to-participate-in-the-lytham-partners-fall-2026-investor-conference.html
RVPH: Patent Filed for New Formulation
August 17, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/rvph-patent-filed-for-new-formulation-165800148.html
Reviva Pharmaceuticals: Reviva Reports Second Quarter 2026 Financial Results and Recent Business Highlights
August 13, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-08/69299534-reviva-pharmaceuticals-reviva-reports-second-quarter-2026-financial-results-and-recent-business-highlights-399.htm
Reviva Pharmaceuticals Files U.S. Patent Application for New Brilaroxazine Formulation, Expects FDA Feedback in Q4 2026
August 12, 2026  |  quiverquant.comQ
Reviva Reports Second Quarter 2026 Financial Results and Recent Business Highlights
August 12, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/12/3344112/0/en/reviva-reports-second-quarter-2026-financial-results-and-recent-business-highlights.html
Reviva Pharmaceuticals to Present at the Life Sciences Investor Forum on June 24th
June 23, 2026  |  financialpost.comF
Reviva Pharmaceuticals to Present at the Life Sciences Investor Forum on June 24th
June 23, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/23/3315885/0/en/reviva-pharmaceuticals-to-present-at-the-life-sciences-investor-forum-on-june-24th.html
Reviva to Participate in Fireside Chat at A.G.P.’s Annual Healthcare Company Showcase
May 18, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/reviva-participate-fireside-chat-g-120000847.html
Reviva to Participate in Fireside Chat at A.G.P.'s Annual Healthcare Company Showcase
May 18, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/18/3296578/0/en/reviva-to-participate-in-fireside-chat-at-a-g-p-s-annual-healthcare-company-showcase.html
OTC Listing Leaves Reviva Pharmaceuticals Shares Vulnerable to Thin Trading and Volatile Price Swings
May 15, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/otc-listing-leaves-reviva-pharmaceuticals-shares-vulnerable-to-thin-trading-and-volatile-price-swings?utm_source=marketbeat.com&utm_medium=referral
Reviva Reports First Quarter 2026 Financial Results and Recent Business Highlights
May 13, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/13/3294478/0/en/reviva-reports-first-quarter-2026-financial-results-and-recent-business-highlights.html
Analysts Offer Insights on Healthcare Companies: Reviva Pharmaceuticals Holdings (RVPH) and Merck & Company (MRK)
April 21, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/MRK-N/pressreleases/1420046/
Maxim Turns Cautious on Reviva Pharmaceuticals Holdings, Inc. (RVPH) Despite Phase 3 Progress Plans
April 20, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/maxim-turns-cautious-on-reviva-pharmaceuticals-holdings-inc-rvph-despite-phase-3-progress-plans-1742248/
Reviva Pharmaceuticals: Reviva Announces Letter to Shareholders
April 15, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-04/68205477-reviva-pharmaceuticals-reviva-announces-letter-to-shareholders-399.htm
Reviva Pharmaceuticals Holdings, Inc. Updates Shareholders on Strategic Direction and Brilaroxazine Development
April 15, 2026  |  quiverquant.comQ
Reviva Pharmaceuticals Holdings (RVPH) price target decreased by 42.03% to 68.00
April 9, 2026  |  msn.comhttps://www.msn.com/en-us/money/other/reviva-pharmaceuticals-holdings-rvph-price-target-decreased-by-42-03-to-68-00/ar-AA20uSCX
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Receives Consensus Rating of “Moderate Buy” from Analysts
April 6, 2026  |  defenseworld.netD
RVPH: Cleared for Takeoff – 2Q:26 Initiation of RECOVER 2
April 1, 2026  |  msn.comhttps://www.msn.com/en-us/health/medical/rvph-cleared-for-takeoff-2q26-initiation-of-recover-2/ar-AA1ZVIdD

New MarketBeat Followers Over Time

Media Sentiment Over Time

Enveric Biosciences stock logo

Enveric Biosciences NASDAQ:ENVB

$1.37 -0.03 (-2.29%)
Closing price 03:59 PM Eastern
Extended Trading
$1.37 +0.00 (+0.15%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida.

Lexaria Bioscience stock logo

Lexaria Bioscience NASDAQ:LEXX

$2.70 -0.10 (-3.57%)
Closing price 03:59 PM Eastern
Extended Trading
$2.70 0.00 (0.00%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.

Orgenesis stock logo

Orgenesis NASDAQ:ORGS

$0.35 +0.28 (+400.00%)
As of 11:07 AM Eastern

Orgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of research institutes and hospitals. Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration. The company also provides development services, including regulatory services, pre-clinical studies, intellectual property services, and GMP process translation, as well as support services; hospital services; cell process development services; and distributed cell processing services. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is headquartered in Germantown, Maryland.

Reviva Pharmaceuticals stock logo

Reviva Pharmaceuticals NASDAQ:RVPH

$0.48 -0.02 (-4.10%)
As of 03:29 PM Eastern

Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas